Literature DB >> 22816019

ACS chemical neuroscience molecule spotlight on Telcagepant (MK-0974).

Corey R Hopkins1.   

Abstract

Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html). MK-0974 is currently being studied in phase III clinical trials.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22816019      PMCID： PMC3369750          DOI： 10.1021/cn200059f

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN： 1948-7193            Impact factor:   4.418


  9 in total

Review 1.  Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.

Authors:  Peer Tfelt-Hansen
Journal:  Headache       Date:  2010-11-10       Impact factor: 5.887

2.  Antimigraine efficacy of telcagepant based on patient's historical triptan response.

Authors:  Tony W Ho; Jes Olesen; David W Dodick; James Kost; Christopher Lines; Michel D Ferrari
Journal:  Headache       Date:  2010-11-04       Impact factor: 5.887

3.  The relative role of genetic and environmental factors in migraine without aura.

Authors:  M Gervil; V Ulrich; J Kaprio; J Olesen; M B Russell
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

4.  CGRP may play a causative role in migraine.

Authors:  L H Lassen; P A Haderslev; V B Jacobsen; H K Iversen; B Sperling; J Olesen
Journal:  Cephalalgia       Date:  2002-02       Impact factor: 6.292

5.  Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.

Authors:  P J Goadsby; L Edvinsson; R Ekman
Journal:  Ann Neurol       Date:  1990-08       Impact factor: 10.422

Review 6.  The global burden of headache: a documentation of headache prevalence and disability worldwide.

Authors:  Lj Stovner; K Hagen; R Jensen; Z Katsarava; Rb Lipton; Ai Scher; Tj Steiner; J-A Zwart
Journal:  Cephalalgia       Date:  2007-03       Impact factor: 6.292

Review 7.  New drugs in migraine treatment and prophylaxis: telcagepant and topiramate.

Authors:  Lars Edvinsson; Mattias Linde
Journal:  Lancet       Date:  2010-04-21       Impact factor: 79.321

8.  Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974).

Authors:  Daniel V Paone; Anthony W Shaw; Diem N Nguyen; Christopher S Burgey; James Z Deng; Stefanie A Kane; Kenneth S Koblan; Christopher A Salvatore; Scott D Mosser; Victor K Johnston; Bradley K Wong; Cynthia M Miller-Stein; James C Hershey; Samuel L Graham; Joseph P Vacca; Theresa M Williams
Journal:  J Med Chem       Date:  2007-10-11       Impact factor: 7.446

9.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321
  9 in total
  1 in total

1.  CGRP receptor activity in mice with global expression of human receptor activity modifying protein 1.

Authors:  Keegan J Bohn; Baolin Li; Xiaofang Huang; Bianca N Mason; Anne-Sophie Wattiez; Adisa Kuburas; Christopher S Walker; Peiyi Yang; Jianliang Yu; Beverly A Heinz; Kirk W Johnson; Andrew F Russo
Journal:  Br J Pharmacol       Date:  2017-04-22       Impact factor: 8.739
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.